REGENERON PHARMACEUTICALS, Inc.
Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to seven FDA-approved treatments and numerous product candidates in development, all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neuromuscular diseases, infectious diseases and rare diseases.
Regeneron is accelerating and improving the traditional drug development process through our proprietary VelociSuite® technologies, such as VelocImmune® which produces optimized fully-human antibodies, and ambitious research initiatives such as the Regeneron Genetics Center, which is conducting one of the largest genetics sequencing efforts in the world.
Johnson & Johnson
Johnson & Johnson Innovative Medicine is leading where medicine is going. Patients inform and inspire our science-based innovations, which continue to change and save lives. With rigorous science and compassion, we confidently address the most complex diseases of our time and unlock the medicines of tomorrow. Therapeutic areas include: Oncology, Immunology, Neuroscience, Cardiopulmonary and Specialty ophthalmology.
THE ANTIBODY SOCIETY
The Antibody Society is an international non-profit association representing individuals and organizations involved in antibody research and development. We engage in activities that broadly benefit our members, and we encourage collaboration between companies, academia and government organizations in the antibody field. We are an authoritative source of information about antibody therapeutics development, which we disseminate via our website, presentations and publications. We also help to organize conferences on topics relevant to antibody research and development. As a global association, the Society can engage with government and international agencies such as the World Health Organization, to discuss issues of importance to the antibody community.
THE EUROPEAN FEDERATION OF IMMUNOLOGICAL SOCIETIES
The European Federation of Immunological Societies (EFIS) is the umbrella organization of 35 European national immunological societies and associations – collectively uniting more than 14,000 individual scientists and clinicians – whose mission is to advance education, training, research and collaboration in immunology and related fields. EFIS’ partner journal, the European Journal of Immunology (EJI), has since 1971 been serving the needs of the immunology community worldwide with objective enthusiasm, focusing on various aspects of basic, clinical and translational immunology. Together, EFIS-EJI are proud to offer financial support to the organizers of high-caliber immunology-themed meetings, workshops and schools that are organized in Europe and are international in nature. Specifically, through its support, the EFIS-EJI partnership aims to enhance interaction between young scientists and established immunologists, by providing funding to offset the participation costs of deserving junior researchers who, without such support, would be unable to attend quality events focusing on immunology and related disciplines. For further details, visit https://efis.org
